Brokerages expect that Mallinckrodt PLC (NYSE:MNK) will post $828.63 million in sales for the current quarter, Zacks Investment Research reports. Seven analysts have issued estimates for Mallinckrodt’s earnings. The highest sales estimate is $841.60 million and the lowest is $816.00 million. Mallinckrodt posted sales of $631.70 million during the same quarter last year, which suggests a positive year over year growth rate of 31.2%. The company is expected to issue its next earnings results on Tuesday, August 6th.

According to Zacks, analysts expect that Mallinckrodt will report full-year sales of $3.28 billion for the current fiscal year, with estimates ranging from $3.25 billion to $3.31 billion. For the next year, analysts anticipate that the firm will report sales of $3.17 billion, with estimates ranging from $2.73 billion to $3.39 billion. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that cover Mallinckrodt.

Mallinckrodt (NYSE:MNK) last announced its earnings results on Tuesday, May 7th. The company reported $1.94 EPS for the quarter, topping the Zacks’ consensus estimate of $1.73 by $0.21. The firm had revenue of $791.00 million during the quarter, compared to analysts’ expectations of $766.27 million. Mallinckrodt had a positive return on equity of 14.22% and a negative net margin of 118.53%. The company’s quarterly revenue was up 4.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.31 EPS.

MNK has been the subject of a number of recent research reports. ValuEngine cut Mallinckrodt from a “hold” rating to a “sell” rating in a report on Tuesday, March 5th. Morgan Stanley set a $32.00 price objective on Mallinckrodt and gave the company a “hold” rating in a report on Thursday, February 28th. SunTrust Banks assumed coverage on Mallinckrodt in a report on Tuesday, March 19th. They set a “hold” rating and a $23.00 price objective for the company. Mizuho boosted their price objective on Mallinckrodt to $26.00 and gave the company a “neutral” rating in a report on Thursday, February 28th. Finally, Canaccord Genuity set a $40.00 price objective on Mallinckrodt and gave the company a “buy” rating in a report on Monday, March 18th. Four equities research analysts have rated the stock with a sell rating, eight have given a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $30.44.

Shares of Mallinckrodt stock opened at $15.16 on Friday. The company has a market capitalization of $1.27 billion, a PE ratio of 1.89, a P/E/G ratio of 0.15 and a beta of 2.12. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.45 and a quick ratio of 1.08. Mallinckrodt has a one year low of $13.45 and a one year high of $36.65.

Hedge funds and other institutional investors have recently modified their holdings of the business. CWM LLC raised its position in Mallinckrodt by 222.8% during the 1st quarter. CWM LLC now owns 1,159 shares of the company’s stock valued at $25,000 after purchasing an additional 800 shares in the last quarter. FNY Investment Advisers LLC raised its position in Mallinckrodt by 210.4% during the 4th quarter. FNY Investment Advisers LLC now owns 2,288 shares of the company’s stock valued at $36,000 after purchasing an additional 1,551 shares in the last quarter. We Are One Seven LLC bought a new stake in Mallinckrodt during the 4th quarter valued at $38,000. QS Investors LLC raised its position in Mallinckrodt by 14.3% during the 4th quarter. QS Investors LLC now owns 4,000 shares of the company’s stock valued at $64,000 after purchasing an additional 500 shares in the last quarter. Finally, Quantamental Technologies LLC bought a new stake in Mallinckrodt during the 4th quarter valued at $80,000.

Mallinckrodt Company Profile

Mallinckrodt plc, together with its subsidiaries, develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands, and Specialty Generics and Amitiza.

Recommended Story: Forex

Get a free copy of the Zacks research report on Mallinckrodt (MNK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Mallinckrodt (NYSE:MNK)

Receive News & Ratings for Mallinckrodt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt and related companies with MarketBeat.com's FREE daily email newsletter.